Did the FDA Allow A Faulty Device to Endanger Patients And Skew Study Results?
For some time, there have been serious questions about the ROCKET-AF trial, the clinical study of the anti-coagulant medication Xarelto (rivaroxaban), prescribed for patients at risk for stroke. The study compared the performance of Xarelto to that of warfarin, the standard treatment for nearly seven decades. Specifically, the medical community has been raising serious concerns about the objectivity and accuracy of the results. At the center of the controversy is a defective blood analysis device, which had been generating tens of thousands of reports over malfunctions – some of which have resulted in serious patient injuries. Questions about ROCKET-AF...
Read More